BLIS Technologies Ltd

BLIS Technologies Ltd maintains a strong liquidity position, with a current ratio of 7.73 and cash and equivalents of NZD 4.2 million, indicating a robust ability to meet short-term obligations. The company's price-to-book ratio of 1.56 and price-to-tangible-book ratio of 1.56 suggest that the market values the company's equity at a moderate premium to its book value. The debt-to-equity ratio of 0.05 indicates a conservative capital structure with minimal leverage. In terms of profitability, BLIS Technologies Ltd reported a net income of NZD 838,000 and an operating income of NZD 467,000, translating to a return on equity of 6.8% and a return on assets of 5.86%. These figures suggest that the company is generating a modest return on its equity and assets, which is in line with the typical performance of firms in the pharmaceuticals industry. The company's revenue is primarily derived from the sale of probiotic solutions, including BLIS K12, BLIS M18, and BLIS Q24, which are marketed in New Zealand, Australia, Asia, Europe, and the United States. While the input data does not provide a detailed breakdown of revenue by segment or geography, the company's products are sold to both manufacturers and wholesale customers, indicating a diversified customer base. BLIS Technologies Ltd has demonstrated a positive growth trajectory, with a revenue of NZD 12.644 million. The company's outlook for the current fiscal year is positive, with a focus on expanding its market presence and product portfolio. The company's capital expenditure of NZD -483,000 indicates a reduction in capital spending, which may be a strategic move to preserve cash and reinvest in high-return opportunities. The risk assessment for BLIS Technologies Ltd indicates a low liquidity risk and a low dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's conservative capital structure and strong cash reserves further mitigate financial risk. The absence of dilution potential and the low risk of equity dilution suggest that the company is not currently under pressure to issue additional shares. Recent events and filings for BLIS Technologies Ltd do not indicate any significant changes in the company's operations or financial strategy. The company continues to focus on its core business of developing and selling probiotic solutions, with no major disruptions or strategic shifts reported in the latest financial data.